Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (361-370 of 419) with videos related to

Pageof 42
Sort By:
Cancer Discovery|January 9, 2025
Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx RenalÁngel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, et al.
The New England Journal of Medicine|September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Cell Reports|May 7, 2020
Representative Sequencing: Unbiased Sampling of Solid Tumor TissueKevin Litchfield, Stacey Stanislaw, Lavinia Spain, et al.
Cancer Discovery|January 8, 2025
Tracking non-genetic evolution from primary to metastatic ccRCC: TRACERx RenalÁngel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, et al.
The New England Journal of Medicine|April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Cancer Cell|March 27, 2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesFrederick Arce Vargas, Andrew J S Furness, Kevin Litchfield, et al.
The New England Journal of Medicine|October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 YearsPaolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Nature Ecology & Evolution|December 24, 2021
Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal studyXiao Fu, Yue Zhao, Jose I Lopez, et al.
Pageof 42

Showing results (361-370 of 419) with videos related to

Sort By:
Pageof 42
Cancer Discovery|January 9, 2025
Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx RenalÁngel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, et al.
The New England Journal of Medicine|September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Cell Reports|May 7, 2020
Representative Sequencing: Unbiased Sampling of Solid Tumor TissueKevin Litchfield, Stacey Stanislaw, Lavinia Spain, et al.
Cancer Discovery|January 8, 2025
Tracking non-genetic evolution from primary to metastatic ccRCC: TRACERx RenalÁngel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, et al.
The New England Journal of Medicine|April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Cancer Cell|March 27, 2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesFrederick Arce Vargas, Andrew J S Furness, Kevin Litchfield, et al.
The New England Journal of Medicine|October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 YearsPaolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Nature Ecology & Evolution|December 24, 2021
Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal studyXiao Fu, Yue Zhao, Jose I Lopez, et al.
Pageof 42